Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
In3Bio Ltd. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The data reveals 2 pending office actions, showing an active prosecution presence. These actions are handled by 2 distinct examiners, which indicates that the company is navigating multiple examination styles. Furthermore, the portfolio is active across 2 distinct art units, suggesting a technical breadth that spans different specialized groups at the USPTO. JUEDES, AMY E is the busiest examiner, currently overseeing 1 busiest examiner pending action.
The distribution of pending office actions across multiple art units requires practitioners to monitor diverse examination trends. Since the busiest examiner pending count is 1, the workload is split among the distinct examiners involved. This variety in personnel and art units within the Biotechnology & Pharmaceuticals sector necessitates a flexible strategy to address the specific requirements of each examiner and technical group. Managing multiple points of contact at the USPTO can provide broader insights into how the company's pharmaceutical claims are being perceived.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618065 | STABILIZED CHIMERIC SYNTHETIC PROTEINS AND THERAPEUTIC USES THEREOF | JUEDES, AMY E | 6d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618065 | STABILIZED CHIMERIC SYNTHETIC PROTEINS AND THERAPEUTIC USES THEREOF | JUEDES, AMY E | 6d |
| 16356483 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | CARTER, SANDRA DILLAHUNT | 34d |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17618065 | STABILIZED CHIMERIC SYNTHETIC PROTEINS AND THERAPEUTIC USES THEREOF | JUEDES, AMY E | 1644 | §102§103§112Other | Non-Final OA | 6d | Pending | Dec 10, 2021 |
| 16356483 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | CARTER, SANDRA DILLAHUNT | 1674 | §112 | Final Rejection | 34d | Pending | Mar 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial